Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-2 of 2

Sort by

Sort Order Select

Journal Articles

Treatment inequities in newly diagnosed diffuse large B-cell lymphoma (DLBCL): Comparing polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) vs rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) among Medicare beneficiaries

John Vaughn, Anthony Masaquel, Carolina Reyes, Farah Hossain, Eric Zuk, Rebecca Straubing, Matthew Davis, Scott Huntington

Blood (2025) 146 (Supplement 1): 4489.

https://doi.org/10.1182/blood-2025-4489

Published: 2025

Journal Articles

Real-world effectiveness of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) among elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL) in the United States

Matthew Matasar, Anthony Masaquel, Carolina Reyes, Farah Hossain, Eric Zuk, Rebecca Straubing, Matthew Davis, Scott Huntington

Blood (2025) 146 (Supplement 1): 4486.

https://doi.org/10.1182/blood-2025-4486

Published: 2025